Allergy Therapeutics plc (LON:AGY)’s share price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $12.13 and traded as high as $11.50. Allergy Therapeutics shares last traded at $11.55, with a volume of 67,392 shares trading hands.

Separately, FinnCap restated a “corporate” rating on shares of Allergy Therapeutics in a research note on Thursday, July 11th.

The company has a debt-to-equity ratio of 6.20, a current ratio of 3.74 and a quick ratio of 3.08. The stock has a market capitalization of $73.16 million and a PE ratio of -23.10. The stock has a 50 day moving average of GBX 12.13 and a two-hundred day moving average of GBX 12.18.

Allergy Therapeutics Company Profile (LON:AGY)

Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.

Read More: The primary rules of Elliott Wave theory

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with's FREE daily email newsletter.